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ABSTRACT
Background: In Namibia, one out of every 25 cases of tuberculosis (TB) is “lost to follow-up” (LTFU).
This has impacted negatively on national efforts to end the disease by 2035. The aim of this study was to
determine the trends and predictors of LTFU under the directly observed treatment short-course (DOTS)
programme in Namibia.
Methods: The study involved a retrospective longitudinal analysis of a nationwide cohort of TB cases
registered under the DOTS programme in Namibia from 2006 to 2015. The trends and predictors of LTFU
among cases in the National Electronic TB Register of the National TB and Leprosy Program were
respectively determined by interrupted time series and multivariate logistic regression analyses using
R-Studio software.
Results: Out of 104203 TB cases, 3775 (3.6%) were LTFU. A quarter (26%) of cases with poor outcomes
were due to LTFU. The annual decline in cases of LTFU was significant between the first (2005–2010) and
second (2010–2015) medium-term plan period for TB programme implementation (p=0.002). The
independent predictors of LTFU were male sex (p=0.004), 15–24 years age group (p=0.03), provider of
treatment (p<0.001), intensive phase (p=0.047) and living in border/transit regions (p<0.001). HIV
co-infection and TB regimen were not significant predictors of LTFU.
Conclusions: There were declining trends in LTFU in Namibia. DOTS programmes should integrate
socioeconomic interventions for young and middle-aged adult male TB cases to reduce LTFU.
@ERSpublications
Loss to follow-up of tuberculosis patients is an important barrier to ending TB in high-TB-
burden countries. The integration of social welfare among young and/or middle-aged men is
critical in reducing loss to follow-up of TB patients. http://bit.ly/395WfBM
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Introduction
Tuberculosis (TB) has had a devastating impact on public health in Africa [1, 2]. In 2018, out of the 10.0
million cases notified, 24% were from the sub-Saharan countries [3]. Of concern is that the region
accounts for 80% of the 1.8 million estimated annual deaths related to TB; this is a disproportionate
impact in terms of mortality [4]. Namibia, with a case notification rate of 442 cases per 100000, is ranked
fifth among countries with highest burden of TB [5, 6]. However, the universal access to community-based
TB care through the Stop-TB and End-TB strategies implemented since 2005 has improved case
identification and treatment outcomes in Namibia [7].
Nevertheless, the gradual rise in incidence of drug-resistant TB (DR-TB) and poor treatment outcomes
such as “lost-to-follow-up” (LTFU) (i.e. an interruption of TB treatment for at least two consecutive
months) and death [7–10] are major barriers to ending TB in Namibia [3, 11–14]. For instance, the
incidence of LTFU among notified cases in Namibia increased from 4% in 2014 to 10% in 2015. Studies in
other low and middle-income countries (LMICs) such as India and Malaysia estimate higher incidences of
LTFU at 19.2 and 24%, respectively [15, 16]. In addition, LTFU is an important risk factor for
re-emergence of TB strains resistant to first-line anti-TB drugs [6]. In 2014, an estimated 300000 cases of
multidrug-resistant (MDR) TB (i.e. resistance to backbone first-line anti-TB medicines, rifampicin and
isoniazid) were notified globally [17]. In the same year Namibia notified 137 MDR-TB and 6 extensively
drug-resistant (XDR) TB (i.e. MDR-TB with resistance to second-line TB drugs, aminoglycosides and/or
fluoroquinolones) cases [10].
The significance of risk factors of LTFU (i.e. patient demographics, socioeconomic status, directly observed
treatment, short-course (DOTS) programme, clinical covariates, TB treatment regimen and HIV
co-infection) on LTFU have been contested across countries [10, 14, 15, 18–24]. In Namibia, despite
universal coverage of high-quality DOTS, little is known about the impact of these factors on poor
treatment outcomes and, in particular, LTFU, hence, the current study intended to determine the
prevalence and determinants of LTFU in the Namibian context.
Methods
Study design and population
The target population was all the new and retreatment cases with drug-sensitive TB initiated on first-line
anti-tuberculosis DOTS regimens. The accessible population was TB cases registered in the National
Electronic Tuberculosis Register (ETR) database over a 10-year period from 2006 to 2015. The study
included all 104300 TB cases registered in the ETR; 3775 of these were LTFU. A patient was considered
LTFU if TB treatment was interrupted for 2 months or more [10, 17]. A retrospective cohort analysis for
trends and predictors of LTFU was conducted. Quarterly trends in LTFU of TB cases in Namibia were
analysed as a proportion of the total number of TB cases registered for each quarter. The main outcome
measure was the effect size (i.e. odds ratio) for predictors for LTFU compared to TB cases that had a
successful treatment outcome (i.e. cured or completed treatment). The study excluded all TB cases whose
treatment outcome had not been registered in the ETR at the time of the study and patients with poor
treatment outcome other than LTFU, (i.e. died, transferred out, treatment failure) (figure 1).
Medium-term plans for TB in Namibia
Since 2004, Namibia has implemented the DOTS strategy under a national strategic plan on TB
implemented under 5-year medium-term plans (MTPs) to improve outcomes. The first MTP was
implemented between 2004–2009, with the main goal of scaling up DOTS to all public health facilities in
Namibia, with the main goal of achieving 85% treatment success rate from 65%, and to strengthen
detection and management of TB cases. The second MTP-II was developed to address gaps in MTP-I and
was implemented between 2015 and 2017 to meet the World Health Organization (WHO) and national
targets for TB. This focused mainly on the expansion and enhancement of access to quality TB treatment,
bacteriological testing and community-based interventions for reduction of cases LTFU. Thus, the
difference in the interventions served as discriminates to assess the effectiveness the two mid-term policy
strategies for time-series analysis [8, 9]
Procedure and data analysis
Data on treatment outcome, patient sociodemographic, clinical and treatment characteristics were
extracted from the ETR and exported to R-Studio software (version 3.3.2) for quantitative analysis. The
main outcome measures were an odds ratio of a TB case registered under DOTS programme getting LTFU
relative to those with a successful treatment outcome (i.e. cured or completed). The covariates included in
the model were patient characteristics, clinical/diagnostic, treatment and DOTS programmatic
characteristics. The patient covariates were age, sex and region of residence. The clinical covariates were
diagnostic or laboratory classification of the TB case, sputum conversion at 2 months and HIV
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co-infection. The programmatic covariates were the TB strategies implemented (i.e. the first and second
MTP for TB and leprosy), DOTS support category and level of health facility. Other clinical covariates
pertained to the treatment regimens and therapy included the DOTS regimen initiated, anti-retroviral
treatment (ART) regimen, type of DOTS provider, and previous prophylaxis with co-trimoxazole
preventive therapy (CPT) and isoniazid preventive therapy (IPT). An interrupted time-series analysis was
performed to determine the changes in level and trend of LTFU among TB cases registered in the DOTS
programme during the implementation of MTP-I (2004–2009) and MTP-II (2010–2015) medium-term
strategies for TB in Namibia. The following segmented regression model was used:
Yt ¼ b0 þ b1T þ b3TXt þ et
Where, Yt is the outcome (i.e. proportion of patients LTFU at time t), T is the time (in years) elapsed
since the start of the study, Xt is a dummy variable indicating the pre-intervention period (coded 0) or the
post-intervention period (coded 1); β0 estimates the baseline outcome at T=0; β1 is an estimate of the
pre-intervention outcome trend (i.e. the change in outcome with time); β2 is an estimate of the change in
outcome immediately after the intervention (i.e. compared to the outcome at the end of the
pre-intervention period); β3 estimates the change in the post-intervention outcome trend compared to the
pre-intervention outcome trend; et represents the random variability not explained by the model.
Adjustment for serial autocorrelation was carried out by using the Durbin–Watson statistic and by
including an autocorrelation parameter in the segmented regression model if necessary.
Bivariate analysis using Chi-squared test or crude odds ratios was used to identify factors associated with
LTFU. Significant factors were subsequently included in the multivariate logistic regression analysis to
adjust odds ratios for confounding for independent predictors for LTFU and to elaborate on the
relationships between multiple variables. The level of significance for the bivariate and multivariate
analyses for a 95% confidence interval was set at a type I error α of 0.05 and β of 0.20 (power 80%) to
detect a significant odds ratio [18].
Ethics
The research and ethics committees of the Ministry of Health and Social Services (MoHSS) (17/3/3/
November 2015) and University of Namibia (SOM/114/2016) approved the study. The need for written
65 113 cases included in analysis for predictors 
and bivariate analyses
    Cases, LTFU n=3775
    Controls, treatment success n=61 338
104 603
patients registered in
the ETR database
included
27 747 cases excluded
   Treatment outcome was not evaluated
11 743 excluded cases with poor
outcomes other than LTFU
    Died n=6456
    Transferred out =3088
    Failed n=2199
76 856
cases included in 
accessible TB cases 
with a treatment 
outcome registered 
in the ETR
TB cases: a total of 104 603 cases were registered
in the ETR and formed the target population
FIGURE 1 Flowchart for tuberculosis (TB) cases included in the analysis. ETR: electronic tuberculosis
register; LTFU: lost to follow-up.
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informed patient consent was waived as the study used retrospective records in the ETR database.
Patient-specific identifiers, such as names, were anonymized or were not extracted or included from the
dataset to ensure confidentiality.
Results
A significant decline in the quarterly trends in LTFU between 2006 and 2015 of 2.5 cases per quarter
(R2=0.45) was observed (figure 2 and table 2). There was a statistically significant decline in the cases of
LTFU per quarter −0.23% (p<0.001) during MTP-I. The cases of LTFU increased slightly at start of
MTP-II. The quarterly trend in LTFU significantly increased by 0.16% (p=0.044) during MTP-II relative
to MTP-I (figure 2 and table 1).
Out of the 104603 TB cases registered, 3775 (3.6%) were LTFU; this ranged between 6.7% and 34.4% by
regions in Namibia. The prevalence of cases LTFU among patients with unsuccessful treatment outcomes
was 24.3% (3775 of 15 518; table 2). The majority of patients LTFU were: male (66%), new TB cases
(74.4%), aged between 25 and 34 years (31.7%), registered at primary healthcare (PHC) clinics (58.6%),
with a diagnosis of pulmonary TB (82.4%), initiated on the standard 2HRZE/4HRE, i.e 2 months of
isoniazid/rifampicin/pyrazinamide/ethambutol combination continued with 4 months of isoniazid/
rifampicin/pyrazinamide/ethambutol regimen (73.6%), and registered during the implementation of the
first MTP for TB (53.1%) (figure 3). One-third of cases of LTFU had TB/HIV co-infection (33.5%) and
the majority of sputum smears of LTFU cases were either negative or not evaluated (55.0%) at the start of
treatment. A higher number of patients who were LTFU had a guardian (i.e. family member/relative,
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FIGURE 2 Trends of lost to follow-up cases in Namibia, 2006–2015. TB: tuberculosis; Q: quarter.
TABLE 1 Model for impact of medium-term plans (MTPs) on loss to follow-up (LTFU)
Coefficients Estimate (95% CI) SE t-value p-value
Level of LTFU at start of MTP-I (β0) 6.67 (5.33–8.04) 0.67 9.93 0.0001
*
Trend in LTFU in MTP-I (β1) −0.23 (−0.37–−0.09) 0.07 −3.32 0.002*
Level change in LTFU in MTP-II (β2) 0.71 (−0.93–2.35) 0.81 0.88 0.385
Trend change in LTFU in MTP-II (β3) 0.16 (0.004–0.32) 0.08 2.08 0.044*
*: p<0.05.
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neighbour) as the main DOTS provider (39.4%; table 2), were in the continuation phase of treatment
(63.73%) and were not taking ART (83.9%). The cases of LTFU were significantly higher in regions with
border, transit, and central business districts such as Khomas and Kunene (p=0.001, figures 3 and 4).
The univariate logistic regression analysis showed a significant association between percentage of cases of
LTFU and young/middle-aged adult patients (15–45 years) (p=0.001), male sex (p=0.001) and region
where TB care was received (p=0.001), known HIV status (p=0.001) and 2-month sputum conversion
(p=0.001). The medicine-related characteristics associated with LTFU: ART (p=0.001), a relative being a
Otjozondjupa
Khomas
Kunene
Oshikoto
Karas
Hardap
National
Oshana
Kavango East
Kavango West
Zambezi
Erongo
Omaheke
Ohangwena
Omusati
1032 2241
323 (34.4%) 617
3775 (3.6%) 11743
172 387
446 1024
263 766
138 409
85 265
88 315
345 1272
295 1155
237 1023
62 269
264 1628
25
LTFU
372
Non-LTFU (χ2=415, p=0.001)
FIGURE 3 Prevalence of loss to follow-up (LTFU) among tuberuculosis cases by geographic region in
Namibia.
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FIGURE 4 Absolute tuberculosis cases lost to follow-up by region in Namibia.
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TABLE 2 Characteristics and factors associated with tuberculosis (TB) cases lost to follow-up (LTFU) in Namibia
Characteristic Total TB treatment outcome df cOR (95% CI) p-value
Successful LTFU
All TB cases 65113 (100.0%) 61338 (94.2%) 3775 (5.8%)
TB strategy employed
MTP-I 30771 (100.0%) 28766 (93.5%) 2005 (6.5%) 1 1.3 (1.2–1.4) 0.000*
MTP-II 34342 (100.0%) 32572 (94.8%) 1770 (5.2%) 1
Region
Khomas 13137 (100.0%) 12105 (92.1%) 1032 (7.9%) 13 1.1 (0.9–1.4) 0.000*
Kavango West 4572 (100.0%) 4335 (94.8%) 237 (5.2%) 0.7 (0.5–0.9) 0.410
Zambezi 2788 (100.0%) 2726 (97.8%) 62 (2.2%) 0.3 (0.2–0.4) 0.007*
Otjozondjupa 4021 (100.0%) 3698 (92.0%) 323 (8.0%) 1.1 (0.9–1.4) 0.000*
Erongo 7852 (100.0%) 7588 (96.6%) 264 (3.4%) 0.4 (0.3–0.6) 0.340
Karas 4122 (100.0%) 3859 (93.6%) 263 (6.4%) 0.9 (0.7–1.1) 0.000*
Hardap 2660 (100.0%) 2522 (94.8%) 138 (5.2%) 0.7 (0.5–0.9) 0.313
Kunene 2069 (100.0%) 1897 (91.7%) 172 (8.3%) 1.2 (0.9–1.5) 0.013*
Ohangwena 6248 (100.0%) 5903 (94.5%) 345 (5.5%) 0.8 (0.6–1.0) 0.251
Omaheke 2847 (100.0%) 2822 (99.1%) 25 (0.9%) 0.1 (0.1–0.2) 0.022*
Oshikoto 6331 (100.0%) 5885 (93.0%) 446 (7.0%) 0.9 (0.8–1.2) 0.000*
Oshana 1593 (100.0%) 1508 (94.7%) 85 (5.3%) 0.7 (0.5–1.0) 0.851
Omusati 5650 (100.0%) 5355 (94.8%) 295 (5.2%) 0.7 (0.5–0.9) 0.042*
Kavango East 1223 (100.0%) 1135 (92.8%) 88 (7.2%) 1 0.007*
Health facility
Hospital 13334 (100.0%) 12348 (92.6%) 986 (7.4%) 2 1.4 (1.2–1.5) 0.000*
PHC clinic 41454 (100.0%) 39240 (94.7%) 2214 (5.3%) 1.0 (0.9– 1–1) 0.000*
Health centre 10325 (100.0%) 9750 (94.4%) 575 (5.6%) 1 0.358
Sex
Male 37479 (100.0%) 34986 (93.3%) 2493 (6.7%) 1 1.5 (1.4–1.6) 0.000*
Female 27634 (100.0%) 26352 (95.4%) 1282 (4.6%) 1
Age years mean±SD 1.27 33.5±16.9 33.9±16.4 0.000*
Age categories years
0–4 4420 (100.0%) 4191 (94.8%) 229 (5.2%) 7 0.9 (0.7–1.1) 0.000*
5–14 3901 (100.0%) 3729 (95.6%) 172 (4.4%) 0.7 (0.6–0.9) 0.202
15–24 8251 (100.0%) 7766 (94.1%) 485 (5.9%) 1.0 (0.8–1.2) 0.006*
25–34 18760 (100.0%) 17564 (93.6%) 1196 (6.4%) 1.1 (0.9–1.3) 0.976
35–44 15447 (100.0%) 14567 (94.3%) 880 (5.7%) 0.9 (0.8–1.1) 0.280
45–54 7734 (0%) 7292 (94.3%) 442 (5.7%) 0.9 (0.8–1.2) 0.718
55–64 3547 (100.0%) 3355 (94.6%) 192 (5.4%) 0.9 (0.7–1.1) 0.766
⩾65 3053 (100.0%) 2874 (94.1%) 179 (5.9%) 1 0.429
First-line TB regimen
2 HRZE/4 HRE 49226 (100.0%) 46673 (94.8%) 2553 (5.2%) 0.7 (0.4–1.1) 0.000*
2 HRZES/1 HRZE/5 HRE 10846 (100.0%) 9883 (91.1%) 963 (8.9%) 4 1.2 (0.8–2.0) 0.135
2 HRZS/1 HRZ/5 HR (children) 304 (100.0%) 288 (94.7%) 16 (5.3%) 0.7 (0.4–1.4) 0.360
2 HRZ/4 HR (children) 4475 (100.0%) 4251 (95.0%) 224 (5.0%) 0.6 (0.4–1.1) 0.329
Other regimens 262 (100.0%) 243 (92.7%) 19 (7.3%) 1 0.111
TB case registered
New 53956 (100.0%) 51162 (94.8%) 2794 (5.2%) 5 0.7 (0.6–0.8) 0.000*
Failure 402 (100.0%) 370 (92.0%) 32 (8.0%) 1.2 (0.8–1.7) 0.000*
Other previously treated 2769 (100.0%) 2508 (90.6%) 261 (9.4%) 1.4 (1.2–1.6) 0.465
Readmission 842 (100.0%) 674 (80.0%) 168 (20.0%) 3.3 (2.7–4.0) 0.000*
Recurrent TB 1069 (100.0%) 974 (91.1%) 95 (8.9%) 1.3 (1.1–1.6) 0.000*
Relapse 6075 (100.0%) 5650 (93.0%) 425 (7.0%) 1 0.029
TB case
New TB case 53956 (100.0%) 51162 (94.8%) 2794 (5.2%) 1 0.6 (0.5–0.6) 0.000*
Previously treated 11157 (100.0%) 10176 (91.2%) 981 (8.8%) 1
Pulmonary TB case 52454 (100.0%) 49345 (94.1%) 3109 (5.9%) 1 1.1 (1.0–1.2) 0.004*
Extrapulmonary TB 12659 (100.0%) 11993 (94.7%) 666 (5.3%) 1
Continued
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DOTS provider (p=0.001), type of TB regimen type (p=0.044), MoHSS MTP-I strategic plan (p=0.001),
and level of healthcare facility for TB care (p=0.002) (table 2).
Independent predictors of LTFU of the DOTS programme in Namibia
A multivariate logistic regression analysis was conducted to identify predictors of LTFU (table 3). A test of
the full model against was statistically significant, indicating that the predictors as a set reliably
distinguished between LTFU and non-LTFU outcomes (χ2=36.6, p=0.001 with df=15). Nagelkerke’s R2 of
0.35 indicated a relationship between prediction and grouping by LTFU. Prediction success overall was
71.7% (60.8% for LTFU and 79.7% for non-LTFU). The Wald criterion demonstrated that MTP-I strategy
implemented by the National TB and Leprosy Program, male sex [19], type of DOTS provider [20], a
2-month sputum conversion; the region in Namibia of DOTS implementation; particularly Otjozondjupa,
Karas and Kunene regions; and the young/middle-age categories (i.e. 15–45 years of age) made a
significant contribution to prediction of LTFU. However, there was no further significant association of
LTFU with HIV status, regimen type and level of DOTS facility.
TABLE 2 Continued
Characteristic Total TB treatment outcome df cOR (95% CI) p-value
Successful LTFU
Site of TB infection
Pulmonary 52273 (100.0%) 49165 (94.1%) 3108 (5.9%) 6 0.9 (0.6–1.2) 0.000*
Lymph nodes 1806 (100.0%) 1732 (95.9%) 74 (4.1%) 0.6 (0.4–0.9) 0.347
Meningitis 731 (100.0%) 680 (93.0%) 51 (7.0%) 1.0 (0.7–1.6) 0.006*
Miliary 781 (100.0%) 740 (94.8%) 41 (5.2%) 0.8 (0.5–1.2) 0.928
Other sites 3509 (100.0%) 3295 (93.9%) 214 (6.1%) 0.9 (0.6–1.2) 0.211
Pleura 5400 (100.0%) 515 5(95.5%) 245 (4.5%) 0.6 (0.4–0.9) 0.476
Bones/joints 613 (100.0%) 571 (93.1%) 42 (6.9%) 1 0.011*
DOTS provider
Guardian (relative/neighbour) 24974 (100.0%) 23482 (94.0%) 1492 (6.0%) 4 0.4 (0.3–0.6) 0.000*
Workplace 592 (100.0%) 566 (95.6%) 26 (4.4%) 0.3 (0.2–0.5) 0.000*
Health facility 22577 (100.0%) 21462 (95.1%) 1115 (4.9%) 0.4 (0.2–0.5) 0.000*
Community health worker 1262 (100.0%) 1230 (97.5%) 32 (2.5%) 0.2 (0.1–0.3) 0.000*
Other 295 (100.0%) 257 (87.1%) 38 (12.9%) 1 0.000*
Baseline sputum smear
Smear negative 12265 (100.0%) 11544 (94.1%) 721 (5.9%) 2 1.0 (0.9–1.0) 0.005*
Smear positive 30863 (100.0%) 29165 (94.5%) 1698 (5.5%) 0.9 (0.8–1.0) 0.282
Smear not done 21985 (100.0%) 20629 (93.8%) 1356 (6.2%) 1 0.001
Sputum not converted
Yes 36769 (100.0%) 33521 (91.2%) 3248 (8.8%) 1 5.1 (4.7–5.6) 0.000*
No 28343 (100.0%) 27816 (98.1%) 527 (1.9%) 1
Sputum smear month 2
Converted to smear negative 16992 (100.0%) 1673 5(98.5%) 257 (1.5%) 2 0.1 (0.10–0.13) 0.000*
Remaining smear positive 2043 (100.0%) 1971 (96.5%) 72 (3.5%) 0.3 (0.2–0.4) 0.000*
Defaulted+died+transferred+not available 11829 (100.0%) 10460 (88.4%) 1369 (11.6% 1 0.000*
On ART therapy
No 8276 (100.0%) 7713 (93.2%) 563 (6.8%) 1 1.6 (1.4–1.8) 0.000*
Yes 13793 (100.0%) 13184 (95.6%) 609 (4.4%) 1
Exposure to IPT
Yes 8713 (100.0%) 8256 (94.8%) 457 (5.2%) 1 1.8 (0.9–3.7) 0.096
No 272 (100.0%) 264 (97.1%) 8 (2.9%) 1
HIV CPT initiated
No 4347 (100.0%) 4103 (94.4%) 244 (5.6%0 1 0.9 (0.8–1.1) 0.912
Yes 19484 (100.0%) 18382 (94.3%) 1102 (5.7%) 1
HIV status
Negative 22719 (100.0%) 21752 (95.7%) 967 (4.3%) 2 0.6 (0.5– 0.6) 0.000*
Positive 22506 (100.0%) 21243 (94.4%) 1263 (5.6%) 0.7 (0.6–0.8) 0.000*
Unknown 4012 (100.0%) 3713 (92.5%) 299 (7.5%) 1 0.000*
df: degrees of freedom; cOR: crude odds ratio; MTP: medium-term plan; PHC: primary healthcare; HRZE: isoniazid/rifampicin/pyrazinamide/
ethambutol; HRE: isoniazid/rifampicin/ethambutol; DOTS: directly observed treatment short-course; ART: anti-retroviral treatment; IPT:
isoniazid preventive therapy; CPT: co-trimoxazole preventive therapy. *: p<0.05.
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TABLE 3 Multivariate logistic regression for predictors of loss to follow-up in Namibia
Covariates aOR (95% CI) p-value
MTP for TB
MTP period I 0.5 (0.30–0.96) 0.037*
MTP period II 1
Region
Karas 18.8 (4.9–73) 0.001*
Otjozondjupa 3.9 (1.0–15.6) 0.001*
Kunene 3.2 (1.0– 4.1) 0.048*
Khomas 1.7 (0.13–23) 0.043*
Kavango West 1.4 (0.5–4.0) 0.681
Zambezi 1.4 (0.5–4.0) 0.491
Erongo 0.4 (0.04–3.8) 0.443
Hardap 0 (0–10.4) 0.430
Ohangwena 0.6 (0.1–7.3) 1.000
Omaheke 1.6 (0.4–2.1) 0.641
Oshikoto 0 (0) 0.499
Oshana 0.7 (0.7) 0.999
Kavango East 1 0.537
Patient sex
Male 2.2 (1.3–3.8) 0.004*
Female 1
Patient age years
0–4 0 (0–451) 0.025*
5–14 14.4 (0.5–281) 1.000
15–24 29.7 (3.1–194) 0.128
25–34 21.6 (2.4–110) 0.003*
35–44 12.2 (1.4–109) 0.006*
45–54 11.5 (1.2–71.6) 0.025*
55–64 6.2 (0.6–0.8) 0.033*
⩾65 1 0.140
DOTS regimen
2 RHZE/4 RHE 1.0 (0.6–1.9) 0.748
Other regimens 1
DOTS provider
Guardian 1.0 (0.3–4.0) 0.001*
Workplace 0.8 (0.03–26.8) 0.886
Health facility 0.3 (0.08–1.2) 0.921
Community health worker 0 (0) 0.085
Other DOTS providers 1 0.999
2 month’s sputum conversion
Smear negative 1.6 (0.9–3.2) 0.047*
Smear positive 0.4 (0.2–1.2) 0.113
Smear not assessed 1 0.116
Anti-retroviral treatment
No 1.9 (0.9–3.9) 0.052
Yes 1
HIV status
Negative 0.8 (0.2–3.0) 0.474
Positive 1.5 (0.4–6.2) 0.776
Unknown 1 0.563
Facility level
Hospital 0.6 (0.2–1.9) 0.511
PHC clinic 0.6 (0.3–1.4) 0.437
Health centre 1 0.247
Constant 0 0.006
aOR: adjusted odds ratio; MTP: medium-term plan; TB: tuberculosis; DOTS: directly observed treatment,
short-course; RHZE: rifampicin/isoniazid/pyrazinamide/ethambutol; RHE: rifampicin/isoniazid/ethambutol;
PHC: primary healthcare. *: p<0.05.
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Discussion
In the sample taken in this study, of all patients notified in Namibia that had a treatment outcome
registered between 2006 and 2016, 1 out of every 25 TB cases registered was LTFU (table 2 and figure 2).
Furthermore, one out of four patients with unsuccessful outcomes was a case of LTFU. The prevalence of
LTFU varied widely between geographical regions in Namibia, 6.6% to 34%. These are higher than the
national (2%) and global benchmarks for LTFU (0%). Studies in other LMICs in Africa and Asia report
the prevalence of LTFU to range between 6% and 24% [15, 21]. This calls for national and regional
specific strategies to be incorporated in the medium and long-term strategic plans for TB to reduce the
burden of LTFU. The strategy should target building capacity in tracing and supporting patients at risk of
LTFU, particularly those registered for DOTS services in border/transit points as well as regions with
central business districts.
Multivariate logistic regression suggested that the TB patients most at risk of LTFU were male patients,
young adults (<45 years), cases registered in the capital city, patients in transit and/or close to geographical
border DOTS access points with high TB notification rates. Several studies have linked LTFU to patients
initiated on therapy at immigration towns like borders and transit points. Similarly to our findings, studies
associate higher LTFU rates among male patients [22–24], the youth or middle aged (34–44 years) [16,
23]. Contrary to our findings, PELTZER et al. [25] found no association between LTFU and male sex in a
population in South Africa. Nonetheless, young adults in LMICs are a high-risk group for unemployment,
HIV, alcohol and drug abuse, smoking, multiple sexual partners that predispose then to TB and poor
outcomes, such as LTFU [12–15]. Secondly, the study demonstrated that the clinical risk factors for LTFU
were new TB cases, a diagnosis of pulmonary TB versus extrapulmonary TB, and sputum conversion at
2 months (i.e. end of the intensive phase of treatment), but not HIV co-infection. Other studies found
association of HIV [14] and regimen-related adverse drug reaction (ADR) [20] with LTFU among TB
cases. Thirdly, the programmatic predictors of LTFU were interventions under the respective MTP strategy
and DOTS support; MTP-II reduced LTFU by 50% (p=0.037). There was no association between the
treatment regimen, ART and previous IPT exposure, HIV status and CPT prophylaxis and the occurrence
of LTFU (p>0.05) (table 2).
Potential limitations of this study should be considered while interpreting the findings. Firstly, the
retrospective data had missing information on the treatment outcome for several patients and were
excluded from the analysis. In addition, we excluded cases with other poor treatment outcomes (i.e. death,
transferred out and failure) and comparisons were made with patients who had a successful treatment
outcome (i.e. cured and completed treatment). There may be many other factors which better explain
LTFU that were not reported in the ETR database used. Nevertheless, the study utilises a nationwide
dataset in a high-TB-burden country over a significant time period (10-year period). This nationwide
study highlights the significance of improving socioeconomic welfare of TB patients to abate LTFU, as TB
is a disease highly prevalent among patients of low socioeconomic backgrounds. Currently strategic goals
of the TB programme in Namibia are mainly case identification and management with limited
socioeconomic interventions among young adults in Namibia.
In conclusion, the study demonstrates a high prevalence LTFU among TB cases registered under the DOTS
programme in Namibia, this is above the global target of 0%. The findings imply that main factors driving
LTFU are related to socioeconomic welfare of young adults who seek temporary employment in regions
that provide temporary working opportunities, including borders and capital towns. This age group is an
important driver for HIV infection in Namibia. The study recommends the integration of socioeconomic
interventions/incentives in DOTS programmes to support young adult TB cases in informal and/or
temporary employments across all regions in Namibia. In addition, there is a need for integration of DOTS
services in workplaces and institutions that provide temporary employment (e.g. construction sites) for
mobile young male adults to enhance continuity of TB treatment and improve outcomes.
Conflict of interest: None declared.
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